

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
日本婦人科腫瘍学会		三上幹男、永瀬 智、宇田川康博、八重樫伸生、片瀨秀隆	子宮体がん治療ガイドライン 2018年版	金原出版	日本	2018	97-116
		<u>Katabuchi H.</u> , Ohba T., Motohara T.	Cell Biology of the Ovary (1st ed. 2018): Stem Cells, Development, Cancer, and Clinical	Springer	Singapore	2018	
宮原 陽、片瀨秀隆	卵巣癌・腹膜癌（卵巣がん診療ガイドライン 2015年版 (2015)	門脇 孝、小室一成、宮地良樹	日常診療に活かす診療ガイドライン UP-TO-DATE 2018-2019	メジカルビュー社	日本	2018	908-912
本原剛志、片瀨秀隆	腫瘍免疫	柴原浩章	実践よくわかる 臨床生殖免疫学入門	中外出版社	日本	2018	23-32
Motohara T., <u>Katabuchi H.</u>	Emerging role of CD44 variant 6 in driving the metastatic journey of ovarian cancerstem cells.	<u>Katabuchi H.</u> , Ohba T., Motohara T.	Cell Biology of the Ovary	Springer	Singapore	2018	73-88
Tashiro H., <u>Katabuchi H.</u>	Molecular Targeted Therapy for Epithelial Ovarian Cancer.	<u>Katabuchi H.</u> , Ohba T., Motohara T.	Cell Biology of the Ovary	Springer	Singapore	2018	153-166

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
西山 正彦	がん領域の専門医制度の展望	腫瘍内科	22(2)	168-173	2018
西山 正彦	群馬大学における「地域オープン・イノベーションR&D人材養成」事業の展開	臨床医薬	34(5)	329-333	2018
西山正彦	がん治療認定医	産科と婦人科	85 suppl.	202-214	2018
Ohtaki Y, Shimizu K, Nishiyama M, et al. (外16名19番目).	Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas	Oncotarget		in press	2019
Handa T, Katayama A, Nishiyama M, Shirabe K, et al. (外11名10番目, 12番目).	Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer	Int J Oncol.	54(3)	833-844	2019
Imamura M, Hirata K, Nishiyama M, et al. (外17名10番目)	Current status of projects for developing cancer-related clinical practice guidelines in Japan and recommendations for the future	Int J Clin Oncol	24(2)	189-195	2019
Horigome E, Fujieda M, Nishiyama M, et al. (外13名15番目).	Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling	Oncotarget	9(77)	34554-34566	2018
Gombodorj N, Yokobori T, Nishiyama M, Shirabe K, et al. (外11名12,13番目).	Current status of projects for developing cancer-related clinical practice guidelines in Japan and recommendations for the future	J Surg Oncol	118(1)	101-108	2018
Rokudai S, Li Y, Nishiyama M, et al. (外5名7番目).	STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis.	Proc Natl Acad Sci U S A	115(21)	E4806-E4814	2018
Kasahara N, Kaira K, Nishiyama M, et al. (外15名14番目).	Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.	Lung Cancer	119	71-77	2018
Arai H, Nobusawa S, Nishiyama M, et al. (外10名10番目).	Myeloid sarcoma arising in malignant phyllodes tumour: clonal relationships revealed by comparative genome-wide analyses	Br J Haematol	181(2)	255-259	2018
宮原 陽, 片瀨秀隆	臓器別がん診療・治療ガイドライン 11) 卵巣がん治療ガイドライン	腫瘍内科	21(4)	448-453	2018.4

相羽恵介, 片瀨秀隆	学会の学術活動と社会的連携活動	日本婦人科 腫瘍学会雑 誌	36(2)	118-123	2018
杉山 徹, 片瀨秀隆, 青木大輔	婦人科癌取り扱い規約の変更の経 緯と要点	日本婦人科 腫瘍学会雑 誌	36(2)	181-185	2018
永瀬 智, 山上 亘, 片瀨秀隆(外3名6番 目).	婦人科悪性腫瘍の登録事業と公 共性	日本婦人科 腫瘍学会雑 誌	36(2)	186-192	2018
境 健爾, 安達美樹, 片瀨秀隆(外9名12番 目).	熊本地震におけるがん診療連携 拠点病院のがん相談支援センタ ーの状況と課題	癌と化学療 法	45(9)	1311-1317	2018
境 健爾, 安達美樹, 片瀨秀隆(外9名12番 目).	熊本地震におけるがん診療連携 拠点病院のがん治療の状況と課 題	癌と化学療 法	45(9)	1319-1325	2018
田代浩徳, 片瀨秀隆	「卵巣腫瘍取り扱い規約」から「卵 巣腫瘍・卵管癌・腹膜癌取り扱い 規約」- 背景と意義	癌の臨床	64(3)	195-202	2018
宮原 陽、 宇田川康博、 片瀨秀隆	癌治療ガイドラインの進歩	日本臨床	76 suppl 2	70-75	2018
Kondo T, Nakamura M, Kawashima J, Matsumura T, Ohba T, Yamaguchi M, Katabuchi H, Araki E.	Hyperemesis gravidarum followed by refeeding syndrome causes electrolyte abnormalities induced rhabdomyolysis and diabetes insipidus.	Endocr J		doi: 10.1507/en docrj.EJ18- 0496. [Epub ahead of print]	2019
Yoneda M, Imamura R, Nitta H, Taniguchi K, Saito F, Kikuchi K, Ogi H, Tanaka T, Katabuchi H, Nakayama H, Imamura T.	Enhancement of cancer invasion and growth via the C5a-C5a receptor system: Implications for cancer promotion by autoimmune diseases and association with cervical cancer invasion.	Oncol Lett	17(1)	913-920	2019
Takeuchi Y, Nakahara K, Katabuchi H, et al. (外6名8番目).	A 23-Year-Old Woman with Sudden-Onset Blindness of the Right Eye.	J Stroke Cerebrovasc Dis		pii: S1052-305 7(18)30731 -6	2019
Ebina Y, Mikami M, Katabuchi H, et al. (外10名9番目)	Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer	Int J Clin Oncol	24(1)	1-19	2019

Motohara T, Masuda K, Morotti M, Zheng Y, El-Sahhar S, Chong KY, Wietek N, Alsaadi A, Karaminejadranjbar M, Hu Z, Artibani M, Gonzalez LS, <u>Katabuchi H</u> , Saya H, Ahmed AA.	An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.	Oncogene		doi: 10.1038/s41388-018-0637-x. [Epub ahead of print]	2018
Watanabe T, Mikami M, <u>Katabuchi H</u> , et al (外12名3番目)	Quality indicators for cervical cancer care in Japan.	J Gynecol Oncol	29(6)	e83	2018
Imamura Y, Tashiro H, Tsend-Ayush G, Haruta M, Dashdemberel N, Komohara Y, Tsuboki J, Takaishi K, Ohba T, Nishimura Y, <u>Katabuchi H</u> , Senju S.	Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell-derived myelomonocytic cells producing interferon beta.	Cancer Sci	109(11)	3403-3410	2018
Erdenebaatar C, Yamaguchi M, Monsur M, Saito F, Honda R, Tashiro H, Ohba T, Iyama KI, <u>Katabuchi H</u> .	Serum Prolactin Contributes to Enhancing Prolactin Receptor and pJAK2 in Type I Endometrial Cancer Cells in Young Women Without Insulin Resistance.	Int J Gynecol Pathol		doi: 10.1097/PGP.0000000000000527. [Epub ahead of print]	2018
Mikami M, Ikeda M, Sato H, Iwase H, Enomoto T, Kobayashi Y, <u>Katabuchi H</u> .	The use of conization to identify and treat severe lesions among prediagnosed CIN1 and 2 patients in Japan.	J Gynecol Oncol	29(4)	e46	2018
Hayata T, Chiga M, Ezura Y, Asashima M, <u>Katabuchi H</u> , Nishinakamura R, Noda M.	Dullard deficiency causes hemorrhage in the adult ovarian follicles	Genes Cells	23(5)	345-356	2018
Saito T, Tabata T, <u>Katabuchi H</u> , et al. (外15名18番目)	Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.	Int J Clin Oncol	23(2)	201-234	2018
Suzuki K, Kobayashi N, <u>Aiba K</u> , at al. (外13名15番目)..	Clinical significance of cancer-related fatigue in multiple myeloma patients	Int J Hematol	108(6)	580-587	2018

Kusumoto T, Sunami E, Aiba K, et al. (外15名15番目).	Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.	Clin Colorectal Cancer	17(2)	e153-e161	2018
Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, Kurosumi M, Shirabe K.	Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.	Sci Rep	9(1)	1583	2019
Yajima T, Hoshino K, Muranushi R, Mogi A, Onozato R, Yamaki E, Kosaka T, Tanaka S, Shirabe K, Yoshikai Y, Kuwano H.	Fas/FasL signaling is critical for the survival of exhausted antigen-specific CD8+ T cells during tumor immune response.	Mol Immunol	107	97-105	2019
Shibuya K, Ohno T, Katoh H, Okamoto M, Shiba S, Koyama Y, Kakizaki S, Shirabe K, Nakano T.	A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger.	Radiother Oncol	132	230-235	2019
Ohtaki Y, Shimizu K, Saitoh JI, Kamiyoshihara M, Mogi A, Nakazawa S, Ohno T, Shirabe K.	Is salvage surgery for patients with lung cancer after carbon ion radiotherapy easy or difficult?	Interact Cardiovasc Thorac Surg		doi: 10.1093/icvts/ivy350. [Epub ahead of print]	2019
Ishii N, Araki K, Shirabe K. et al (外13名16番目).	Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts.	Cancer Sci	110(1)	334-344	2019
Obayashi K, Shimizu K, Nakazawa S, Ohtaki Y, Kawatani N, Takashi I, Yajima T, Mogi A, Shirabe K.	A leopard can't change its spots: can a T790M mutation-positive cancer change its spots after epidermal growth factor receptor-tyrosine kinase inhibitor therapy?	J Thorac Dis	10(Suppl 33)	S4113-S4116	2018
Shimizu K, Ohtaki Y, Nakazawa S, Obayashi K, Nagashima T, Yajima T, Mogi A, Shirabe K.	Minimally invasive open-window thoracostomy using wound edge protectors.	Ann Thorac Surg		pii: S0003-4975(18)31783-1	2018

Ohtaki Y, Kaira K, Shirabe K, et al. (外17名18番目).	Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.	Am J Transl Res	10(10)	3243-3253	2018
Watanabe A, Harimoto N, Araki K, Yoshizumi T, Arima K, Yamashita Y, Baba H, Tetsuya H, Kuwano H, Shirabe K.	A new strategy based on fluorodeoxyglucose-positron emission tomography for managing liver metastasis from colorectal cancer.	J Surg Oncol	118(7)	1088-1095	2018
Suzuki M, Yokobori T, Gombodorj N, Yashiro M, Turtoi A, Handa T, Ogata K, Oyama T, Shirabe K, Kuwano H.	High stromal transforming growth factor β -induced expression is a novel marker of progression and poor prognosis in gastric cancer.	J Surg Oncol	118(6)	966-974	2018
Okabe H, Yoshizumi T, Shirabe K, et al. (外12名13番目).	Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma.	PLoS One	13(9)	e0203856	2018
Tsukagoshi M, Wada S, Hirono S, Yoshida S, Yada E, Sasada T, Shirabe K, Kuwano H, Yamaue H.	Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer.	Oncotarget	9(59)	31448-31458	2018
Kurozumi S, Joseph C, Shirabe K. (外15名13番目).	Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.	Breast Cancer Res Treat	172(1)	61-68	2018
Harimoto N, Yoshizumi T, Shirabe K. (外15名17番目).	Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study.	Ann Surg Oncol	25(11)	3316-3323	2018
Hidaka M, Eguchi S, Okuda K, Beppu T, Shirabe K, et al. (外9名5番目).	Impact of Anatomical Resection for Hepatocellular Carcinoma With Microportal Invasion (vp1): A Multi-institutional Study by the Kyushu Study Group of Liver Surgery.	Ann Surg		doi: 10.1097/SLA.0000000000002981. [Epub ahead of print]	2018

Tatsuki H, Yokobori T, Katayama C, Kato R, Takahashi R, Osone K, Takada T, Yajima R, Motegi Y, Ogawa H, Fujii T, Shirabe K, Kuwano H, Asao T.	A novel one-step lens cleaning device using air and water flow for endoscopic surgery.	PLoS One	13(7)	e0200749	2018
Shimoda Y, Ubukata Y, Shirabe K, et al. (外17名19番目).	High expression of forkhead box protein C2 is associated with aggressive phenotypes and poor prognosis in clinical hepatocellular carcinoma.	BMC Cancer	18(1)	597	2018
Kurozumi S, Joseph C, Shirabe K, et al. (外13名10番目).	Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.	Breast Cancer Res Treat	170(3)	525-533	2018
Watanabe A, Araki K, Harimoto N, Kubo N, Igarashi T, Ishii N, Yamanaka T, Hagiwara K, Kuwano H, Shirabe K.	D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer.	Int J Clin Oncol	23(4)	689-697	2018
Araki K, Kubo N, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kuwano H, Shirabe K.	Left Lobe Mobilization Strategy of Right-Sided Major Hepatectomy for Treatment of a Tumor Causing Severe Inferior Vena Cava Compression: A Novel Strategy Using the Modified Liver-Hanging Maneuver.	Ann Surg Oncol	25(5)	1150-1151	2018
Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, Narimatsu H, Mizokami M.	Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.	J Gastroenterol	53(7)	819-826	2018
藤也寸志、北川雄光、丹黒章、松原久裕	特別企画「診療ガイドラインの再評価-今後の方向性-」食道癌診療ガイドラインのあり方に関する考察と今後の方向性	日本外科学会雑誌	119(5)	569-571	2018
藤也寸志、中司悠、中ノ子智徳、杉山雅彦、太田光彦、池部正彦	食道癌 / 新規治療開発研究.	日本臨牀食道癌(第2版)	76 Suppl 8	466-473	2018
森田勝、杉山雅彦、太田光彦、池部正彦、藤也寸志	食道癌の罹患率と死亡率の現況(海外).	日本臨牀食道癌(第2版)	76 Suppl 8	38-44	2018

Yamamoto M, Shimokawa M, Kawano H, Ohta M, Yoshida D, Minami K, Ikebe M, Morita M, <u>Toh Y.</u>	Benefits of laparoscopic surgery compared to open standard surgery for gastric carcinoma in elderly patients: propensity score-matching analysis.	Surg Endosc	33(2)	510-519	2019
Yoshida N, Yamamoto H, Baba H, Miyata H, Watanabe M, <u>Toh Y.</u> , Matsubara H, Kakeji Y, Seto Y.	Can Minimally Invasive Esophagectomy Replace Open Esophagectomy for Esophageal Cancer? Latest Analysis of 24,233 Esophagectomies From the Japanese National Clinical Database.	Ann Surg		doi: 10.1097/SLA.0000000000003222. [Epub ahead of print]	2019
Motoyama S, Maeda E, Yano M, Yasuda T, Ohira M, Doki Y, <u>Toh Y.</u> , Higashi T, Matsubara H; Japan Esophageal Society	Appropriateness of the institute certification system for esophageal surgeries by the Japan Esophageal Society: evaluation of survival outcomes using data from the National Database of Hospital-Based Cancer Registries in Japan.	Esophagus	16(1)	114-121	2019
Kitagawa Y, Uno T, <u>Toh Y.</u> , et al. (外 17 名 11 番目).	Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 2.	Esophagus	16(1)	25-43	2019
Kitagawa Y, Uno T, <u>Toh Y.</u> , et al. (外17名 11番目).	Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1.	Esophagus	16(1)	1-24	2019
Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Masuda M, Endo S, <u>Toh Y.</u> , et al. et al. (外18名16番目).	Thoracic and cardiovascular surgery in Japan during 2015 : Annual report by The Japanese Association for Thoracic Surgery.	Gen Thorac Cardiovasc Surg	66(10)	581-615	2018
Sugimachi K, Sakimura S, Kuramitsu S, Hirata H, Niida A, Iguchi T, Eguchi H, Masuda T, Morita M, <u>Toh Y.</u> , Maehara Y, Suzuki Y, Mimori K.	Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy	Br J Cancer	119(4)	419-423	2018

Yamaguchi S, Morita M, Yamamoto M, Egashira A, Kawano H, Kinjo N, Tsujita E, Minami K, Ikebe M, Ikeda Y, Kunitake N, <u>Toh Y.</u>	Long-Term Outcome of Definitive Chemoradiotherapy and Induction Chemoradiotherapy Followed by Surgery for T4 Esophageal Cancer with Tracheobronchial Invasion.	Ann Surg Oncol	25(11)	3280-3287	2018
Tachimori Y, Ozawa S, <u>Toh Y</u> , et al. (外7名8番目); Registration Committee for Esophageal Cancer of the Japan Esophageal Society.	Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan, 2011	Esophagus	15(3)	127-152	2018
Seki N, Natsume M, Ochiai R, Haruyama T, Ishihara M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ota S, Ichikawa Y, <u>Watanabe K.</u>	Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy.	Case Rep Oncol	12(1)	91-97	2019
Seki N, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ota S, Ichikawa Y, <u>Watanabe K.</u>	Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush.	Case Rep Oncol	12(1)	84-90	2019
Ota S, Fujigaki Y, Tamura Y, Kojima K, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ichikawa Y, <u>Watanabe K.</u> Seki N.	Significance of Earlier Initiation of Chemotherapy for Lung Cancer Complicated with Primary or Secondary Nephrotic Syndrome following Its Appropriate Differential Diagnosis.	Case Rep Oncol	12(1)	53-58	2019

Ota S, Sakamoto T, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Tanzawa S, Usui R, Honda T, Ichikawa Y, <u>Watanabe K</u> , Sasajima Y, Mizota A, Seki N.	Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review.	Case Rep Oncol	12(1)	47-52	2019
Natsume M, <u>Watanabe K</u> , Matsumoto S, Naruge D, Hayashi K, Furuse J, Kawamura M, Jinno H, Sano K, Fukushima R, Osawa G, Aruga E, Hashiguchi Y, Tanaka A, Takikawa H, Seki N.	Factors Influencing Cancer Patients' Choice of End-of-Life Care Place.	J Palliat Med	21(6)	751-765	2018